01—Abstract
Summary
Summary of the 10-Q filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation's first-quarter 2025 Form 10-Q reports total revenues of $794.4 milliona, up from $677.7 million in the prior-year quarter, with net income of $322.2 million versus $306.6 million.
Diluted earnings per share were $6.63b compared with $6.17. Growth was led by Tyvaso DPI, whose net product sales rose to $302.5 million from $227.5 million, while total Tyvaso net product sales reached $466.3 million. Operating income was $382.8 million, and research and development expense increased to $149.0 million from $104.1 million, primarily reflecting a $30.0 million increase in milestone payments for drug delivery device technologies.
The balance sheet strengthened over the quarter. Cash and cash equivalents rose to $1,899.9 millionc, and total cash and marketable investments were $5,032.0 million at March 31, 2025. Operating cash flow was $461.2 million.
Total debt under the 2022 Credit Agreement was reduced to $200.0 milliond, which was then refinanced on April 25, 2025 through a new unsecured revolving credit facility of up to $2.5 billion maturing in 2030, with $200.0 million borrowed and outstanding as of April 30, 2025. The filing highlights material legal and competitive risks. The Sandoz litigation carries an accrued liability of $71.1 million recorded in 2024 plus $0.7 million through the first quarter of 2025, and all parties have appealed.
Liquidia received tentative FDA approval for Yutrepia, a dry powder competitor to Tyvaso DPI, with exclusivity expiring May 23, 2025, and a PDUFA goal date of May 24, 2025. Liquidia also filed a new patent infringement lawsuit against Tyvaso DPI on April 21, 2025. The company has budgeted approximately $750 million for capital expenditures from the second quarter of 2025 through 2027, mainly for manufacturing and xenotransplantation facilities.
02—Key points
Key Highlights
- Total revenues rose to $794.4 million from $677.7 million, with Tyvaso DPI net product sales up to $302.5 million from $227.5 million.
- Net income was $322.2 million, compared with $306.6 million, and diluted EPS was $6.63 versus $6.17.
- Research and development expense increased to $149.0 million from $104.1 million, including a $30.0 million increase in milestone payments for drug delivery device technologies.
- Cash and cash equivalents were $1,899.9 million, and total cash and marketable investments were $5,032.0 million at March 31, 2025.
- A new $2.5 billion unsecured revolving credit facility was entered into on April 25, 2025, maturing in 2030, with $200.0 million borrowed to repay the 2022 Credit Agreement.
- Liquidia has tentative FDA approval for Yutrepia, with exclusivity expiring May 23, 2025, and Liquidia filed a new patent lawsuit against Tyvaso DPI on April 21, 2025.
- The Sandoz litigation carries a $71.1 million accrued liability recorded in 2024 plus $0.7 million in 2025, and all parties have appealed the final judgment.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, United Therapeutics kept $0.41.
- Revenue$794.4M100.0%
- Cost of revenue−$92.5M11.6%
- Gross profit$701.9M88.4%
- Operating costs−$319.1M40.2%
- Operating income$382.8M48.2%
- Interest, other & tax−$60.6M7.6%
- Net income$322.2M40.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 30, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $794.40M$677.70M | +17.2% |
| Cost of Revenue | $92.50M$72.90M | +26.9% |
| Gross Profit | $701.90M$604.80M | +16.1% |
| R&D Expenses | $149.00M$104.10M | +43.1% |
| SG&A Expenses | $170.10M$144.40M | +17.8% |
| Operating Expenses | $411.60M$321.40M | +28.1% |
| Operating Income | $382.80M$356.30M | +7.4% |
| Net Income | $322.20M$306.60M | +5.1% |
| EPS (Basic) | $7.18$6.52 | +10.1% |
| EPS (Diluted) | $6.63$6.17 | +7.5% |
| Shares Outstanding (Basic) | 44.90M47.00M | −4.5% |
| Shares Outstanding (Diluted) | 48.60M49.70M | −2.2% |
05—Questions
Frequently Asked Questions
How did United Therapeutics' revenue and profitability change in the first quarter of 2025?
Total revenues increased to $794.4 million from $677.7 million, and operating income rose to $382.8 million from $356.3 million. Net income was $322.2 million versus $306.6 million, and diluted EPS was $6.63 compared with $6.17 a year earlier.
What drove growth in product sales?
Tyvaso DPI net product sales rose to $302.5 million from $227.5 million, driven mainly by higher quantities sold and, to a lesser extent, a price increase. Total Tyvaso net product sales grew to $466.3 million from $372.5 million, and Orenitram sales increased to $120.7 million from $106.2 million.
What is the company's liquidity and debt position?
Cash and cash equivalents totaled $1,899.9 million and total cash and marketable investments were $5,032.0 million at March 31, 2025. The 2022 Credit Agreement balance of $200.0 million was repaid through a new $2.5 billion revolving credit facility entered into on April 25, 2025, and $200.0 million remained outstanding as of April 30, 2025.
What are the main competitive threats disclosed in the filing?
The filing states that Liquidia has tentative FDA approval for Yutrepia, a dry powder treprostinil product, following expiration of exclusivity on May 23, 2025, and that its PDUFA goal date is May 24, 2025. If launched, Yutrepia would compete directly with Tyvaso DPI and nebulized Tyvaso, and the company says its Tyvaso DPI revenues could be materially adversely affected.
What significant litigation exposure does the company disclose?
The Sandoz breach of contract judgment resulted in a liability of $71.1 million accrued during 2024 and an additional $0.7 million through the first quarter of 2025, with all parties appealing. Separately, Humana, United Healthcare, and MSP Recovery have filed lawsuits over charitable donations, and Liquidia filed a new patent infringement suit against Tyvaso DPI in April 2025.
06—Continue